Key result
High H2FPEF score is linked to ~3.5-fold higher risk of HF hospitalization and death in HCM.
Why the study?
Do H2FPEF and HFA-PEFF scores predict the risk of heart failure hospitalization and all-cause death in patients with hypertrophic cardiomyopathy?
Cohort (n=1,068)
Do H2FPEF and HFA-PEFF scores predict the risk of heart failure hospitalization and all-cause death in patients with hypertrophic cardiomyopathy?
Both H2FPEF and HFA-PEFF scores demonstrate prognostic value for predicting heart failure hospitalization and all-cause death in patients with hypertrophic cardiomyopathy, despite frequent discordance in patient classification.
Answers are grounded in this paper and cite their sources.
Supports prognostic stratification with both scores in HCM; leaves open optimal integration amid discordance.
Aims H2FPEF and HFA-PEFF scores have demonstrated prognostic value in heart failure (HF) with preserved ejection fraction. This study aimed to explore the value of the H2FPEF and HFA-PEFF scores for HF risk stratification in patients with hypertrophic cardiomyopathy (HCM). Methods and results In this cohort study, 1068 HCM patients were included. Then the H2FPEF and HFA-PEFF scores were calculated to categorize patients into low, intermediate, and high score groups. The primary endpoint was a composite of the first HF hospitalization and all-cause death. 594 (55.6%) patients were classified discordantly. After a follow-up period of 3.1 ± 2.1 years, 85 (8.0%) patients were admitted for HF for the first time, and 62 (5.8%) patients died. Rates of first HF hospitalization and all-cause death per 1000 person-years for the low, intermediate, and high H2FPEF score groups were 25.0 (95% confidence interval [CI]: 14.5–35.4), 52.0 (95% CI: 41.6–62.3), and 148.1 (95% CI: 77.7–218.5), respectively. For the low-intermediate and high HFA-PEFF score groups, rates were 19.3 (95% CI: 11.6–27.0) and 69.3 (95% CI: 56.4–82.1), respectively. Intermediate H2FPEF score (hazard ratio [HR]: 1.820, 95% CI: 1.135–2.919; P = 0.013), high H2FPEF score (HR: 3.464, 95% CI: 1.774–6.765; P < 0.001), and high HFA-PEFF score (HR: 2.414, 95% CI: 1.501–3.882; P < 0.001) were each independently associated with an increased risk of the primary endpoint. Intermediate-high H2FPEF score demonstrated an equal risk for the primary endpoint compared to the high HFA-PEFF score (HR: 0.826, 95% CI: 0.636–1.072; P > 0.05). Obesity (HR: 1.958, 95% CI: 1.140–3.363; P = 0.015), atrial fibrillation (HR: 1.686, 95% CI: 1.071–2.654; P = 0.024), pulmonary hypertension (HR: 1.613, 95% CI: 1.032–2.521; P = 0.036) of the H2FPEF score, and the morphological major criterion (HR: 1.601, 95% CI: 1.084–2.364; P = 0.018) and functional major criterion (HR: 2.340, 95% CI: 1.442–3.797; P < 0.001) of the HFA-PEFF score were independent predictors of the primary endpoint. A new algorithm was constructed using the independent predictors from both scores, with the functional major criterion weighted as 2 points and the others as 1 point. The H2FPEF score, HFA-PEFF score, and the new algorithm demonstrated C-indices of 0.594, 0.651, and 0.681, respectively. Conclusions There is discordance in the classification of patients with HCM using the H2FPEF and HFA-PEFF scores. Both scores demonstrated prognostic value in risk stratification for HF hospitalization and all-cause death in HCM patients. Future studies should develop and validate a new algorithm integrating both scores.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2025) conducted a cohort in Hypertrophic cardiomyopathy (n=1,068). High H2FPEF and HFA-PEFF scores vs. Low scores was evaluated on Composite of the first HF hospitalization and all-cause death (HR 3.464, 95% CI 1.774-6.765, p=<0.001). High H2FPEF and HFA-PEFF scores independently predicted increased risk of HF hospitalization and death in HCM patients.
Synapse has enriched 10 related papers. Consider them for comparative context: